Published in:
Open Access
01-12-2016 | Review
Second-generation inhibitors of Bruton tyrosine kinase
Authors:
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu
Published in:
Journal of Hematology & Oncology
|
Issue 1/2016
Login to get access
Abstract
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib. This review summarizes the clinical development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.